NewTimeSpace | Market Anxiety Prevails Despite Profitable Results: Distinct Healthcare (02677.HK) Accelerates Decline by Over 30%

Recently, Distinct Healthcare (02677.HK) released its first annual report since listing. For the full year, revenue reached RMB 1.065 billion, a year-on-year increase of 11.1%, while net profit hit RMB 135 million, a significant surge of 61.2% year-on-year.

However, these stellar financial results failed to boost the stock price. NewTimeSpace understands that since its listing on February 6, 2026, the company’s stock has trended downward, characterized by "opening high and moving lower under persistent pressure." The release of the annual report on March 25 provided no relief; instead, the decline accelerated.

As of the close on March 30, 2026, Distinct Healthcare was quoted at HK$38.26, falling 15.58% on the day and marking a cumulative drop of over 30% since March 25.

China’s Third-Largest Private Mid-to-High-End Medical Institution; Trading 35% Below Offer Price

Public records show that Distinct Healthcare was founded in 2012. As a private mid-to-high-end integrated medical service provider, it strategically focuses on the premium healthcare market. Its target clients are typically mass-affluent individuals with strong purchasing power who prefer personalized medical services.

The company generates revenue primarily through its private medical institutions and an online healthcare platform. Its business covers a range of specialties, including pediatrics, dentistry, ophthalmology, dermatology, ENT, surgery, gynecology, and internal medicine. It also provides comprehensive services such as general consultation, diagnostic and preventive healthcare, treatment, and pharmaceutical sales.

According to Frost & Sullivan, based on 2024 revenue, Distinct Healthcare is the third-largest private mid-to-high-end integrated medical service institution in China, with a market share of 2%. As of December 31, 2024, the company ranked first in terms of the number of Chinese cities covered and second in terms of paid patient visits among all private mid-to-high-end integrated medical groups.

NewTimeSpace understands that Distinct Healthcare currently owns and operates 20 medical institutions (18 clinics and 2 hospitals) across 10 major Chinese cities, including Shenzhen, Guangzhou, Beijing, Chengdu, Suzhou, Changsha, Shanghai, Chongqing, Hangzhou, and Wuhan.

In terms of its business model, Distinct Healthcare utilizes high-demand pediatric services as a "traffic entry point" to attract other family members for medical consultations.

Industry insiders point out that for chain medical service enterprises, the core constraint lies in service standardization. If improvements in per-capita efficiency are limited or if the company relies too heavily on core doctors, its expansion will hit a "management ceiling," making it difficult for its valuation model to align with mature consumer or chain service companies.

Since its IPO, Distinct Healthcare has struggled to find favor in the capital market. By March 30, 2026, the stock closed at HK$38.26, a single-day plunge of 15.58%, representing a 36.13% drop from its offer price of HK$59.90.

Turning Profitable: Physical Medical Services Account for Over 90% of Revenue

On March 25, 2026, Distinct Healthcare released its inaugural post-listing annual report.

Reviewing the performance disclosed in its prospectus prior to listing, the company achieved significant revenue growth between 2022 and 2024, with total revenue rising from RMB 473 million to RMB 959 million, representing a compound annual growth rate (CAGR) of 42.3%.

In 2024, the company relied on fair value gains from convertible redeemable preferred shares and cost-cutting measures to generate a gain of RMB 129 million, which directly pushed the company into profitability that year.

However, from 2021 to 2024, Distinct Healthcare’s core operating profit remained negative for four consecutive years, recorded at -RMB 109 million, -RMB 138 million, -RMB 67 million, and -RMB 47 million, respectively. Thus, 2025 marked the true turning point for the company’s profitability.

Financial data released by Distinct Healthcare shows that in 2025, revenue reached RMB 1.065 billion (+11.1% YoY), gross profit was RMB 267 million (+18.2% YoY), and net profit hit RMB 131 million (+61.2% YoY).

While the company has turned a profit, its revenue growth rate has noticeably slowed. Specifically, physical medical services remain the core pillar, with the segment contributing RMB 980 million (including M&A) in 2025, accounting for 92.02% of total revenue.

Distinct Healthcare’s revenue is derived from physical medical services, online medical services, membership plans, and out-of-hospital services. Currently, the share of its diversified business segments remains low.

Regarding the growth structure, physical health service visits reached 831,600 in 2025, a 13.9% increase from 730,300 in 2024. The average cost per visit remained at RMB 1,179, largely flat compared to 2024. Revenue growth was primarily driven by the expansion of patient volume.

Among traditional core departments, Dermatology accounted for 25% of revenue, making it the largest department. Dentistry accounted for 19%, Ophthalmology for 14%, and Adult Health Management and Checkups for 18%. Together, these four departments contribute 76% of revenue, forming the backbone of the company's income.

Notably, the Pediatrics and Child Healthcare segment saw a slight year-on-year revenue decline of 5.5%, affected by the falling birth rate and the impact of AI on the diagnosis and treatment of common illnesses. Among emerging departments, Rehabilitation and Physical Therapy revenue accounted for 2% (+146.5% YoY), Psychiatry and Psychology for 1% (+119.8% YoY), and ENT and Surgery revenue grew by 5.9% year-on-year.

Geographically, Tier-1 cities remain the primary source of income, with Beijing, Shanghai, Guangzhou, and Shenzhen collectively contributing over 70% of total revenue. New Tier-1 cities generally showed growth, becoming new regional highlights. Revenue in Wuhan saw a slight downward adjustment due to the integration of acquired entities and the termination of medical insurance settlements.

Low Industry Concentration; Intense Competition in the Premium Medical Market

NewTimeSpace understands that the private mid-to-high-end medical service market where Distinct Healthcare operates is characterized by "low concentration and high competition."

By 2024 revenue, the company’s market share was only 2.0%, ranking third in the industry—well behind United Family Healthcare (6.8%) and Jiahui Health (3.2%).

Industry trends suggest that Distinct Healthcare is facing competitive pressure from multiple directions. Among its rivals, United Family Healthcare possesses 11 hospitals, 24 clinics, 1,200 beds, and over 600 full-time doctors, whereas Distinct Healthcare has only 19 institutions and 387 full-time doctors, representing a significant scale gap.

Furthermore, foreign-funded hospitals are accelerating their entry. China now allows the establishment of wholly foreign-owned hospitals in nine locations, including Beijing, Shanghai, and Guangzhou. Tianjin Perennial Hospital has already become the nation’s first wholly foreign-owned Grade 3 integrated hospital. Additionally, the international departments of public hospitals are expanding; for example, the international department of Shanghai Zhongshan Hospital reached annual revenues of RMB 400-500 million within two years of its founding, leveraging top-tier doctor resources and medical insurance reimbursement channels to divert high-end clients.

NewTimeSpace notes that several domestic medical groups, such as Lianchi Hospital and BenQ Medical Center, have recently sought Hong Kong IPOs. Since its debut, BenQ Medical Center’s stock has followed a similar downward trajectory to that of Distinct Healthcare.

Industry insiders point out that as the number of players continues to increase, the mid-to-high-end medical demand originally concentrated in leading firms is being further diverted.

It is worth mentioning that Distinct Healthcare plans to expand its network through organic growth and strategic acquisitions. However, the 2024 acquisition of Wuhan Shenlong Tianxia resulted in RMB 134 million in goodwill; if integration falls short of expectations, the company faces impairment risks. Given that Wuhan’s revenue has already dipped due to integration issues and insurance settlement changes, the success of future integration remains to be seen.

For investors, Distinct Healthcare's challenge lies in whether it can defend its core middle-class client base under the multi-pronged assault of foreign hospitals, public international departments, and specialty clinic chains.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.